Page 153 - Binder2

With the immunologists who know what the system’s
missing.
With the developers who are willing to build slower—but
smarter.
With the regulators who understand that approval means
nothing if the drug fails a year later.
With the payers who are ready to back durability with
reimbursement muscle.
And with patients who deserve better than a rotating door
of high-cost hope.

This Is the Future We Could Build—If We Have
the Will

The immune system is not a wall.
It’s not a black box.
It’s not a trap waiting to spring.

It’s a learning system—and we’ve only begun to speak its
language.

We can build therapies it understands.
We can design for permanence.
We can reimagine biologics not just as powerful, but as
welcome.

Because what comes next won’t be defined by who binds
best.
It’ll be defined by who lasts longest—without being
thrown out.

The immune-compatible future isn’t a fantasy.
It’s the next logical step.
And the blueprint is already unfolding.

151